THE WOODLANDS, Texas, Feb. 7, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the 2012 BIO CEO & Investor Conference in New York on Tuesday, February 14, 2012 at ... read more

THE WOODLANDS, Texas, Jan. 9, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today top-line results from the first clinical study testing the combined effects of LX4211, a novel sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, with the dipeptidyl peptidase 4 (DPP-4) ... read more

THE WOODLANDS, Texas, Jan. 4, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Dr. Arthur T. Sands, president and chief executive officer, will present at the J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 11, 2012 at 9:00 a.m. Pacific Time. ... read more

THE WOODLANDS, Texas, Dec. 23, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has completed its previously announced rights offering pursuant to an effective shelf registration statement. Under the rights offering, an aggregate of 142,492,883 shares of common stock will ... read more

THE WOODLANDS, Texas, Nov. 22, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has commenced its previously announced rights offering pursuant to an effective registration statement and today began mailing a prospectus and other rights offering materials to its stockholders. In the rights offering, stockholders will receive ... read more

THE WOODLANDS, Texas, Nov. 11, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced plans for a rights offering pursuant to an effective shelf registration statement in which its stockholders will receive non-transferable subscription rights to purchase up to 144,247,800 shares of its common stock in the aggregate. In the ... read more

THE WOODLANDS, Texas, Nov. 9, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. Roy Fleischmann from the University of Texas Southwestern Medical Center will be presenting data from Lexicon's LX2931 Phase 2 proof-of-concept clinical trial ... read more

THE WOODLANDS, Texas, Nov. 3, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. David Powell, senior vice president of metabolism research, will present data from clinical and preclinical studies of LX4211, a dual inhibitor of ... read more

THE WOODLANDS, Texas, Nov. 1, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2011. "Recent positive results from clinical ... read more

THE WOODLANDS, Texas, Oct. 21, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that data from its Phase 2 clinical studies of telotristat etiprate (LX1032) will be presented this weekend at the annual meeting of the North ... read more

THE WOODLANDS, Texas, Sept. 13, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, reported positive data from a recently completed clinical trial and mechanistic study of LX4211, a dual inhibitor of the sodium glucose transporters 1 and 2 (SGLT1 ... read more

THE WOODLANDS, Texas, Sept. 13, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company is presenting clinical data this week at the European Association for the Study of Diabetes (EASD) annual meeting in Lisbon, Portugal. Data ... read more

THE WOODLANDS, Texas, Sept. 6, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Morgan Stanley Global Healthcare Conference in New York ... read more

THE WOODLANDS, Texas, Aug. 30, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Stifel Nicolaus Healthcare Conference in Boston on Wednesday, ... read more